Cancer remains the leading driver of healthcare costs for employers, with a significant rise in cases among people under 50. 1, 2 MSK Direct addresses this challenge, helping benefits leaders ...
On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj ®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback